Dynavax Technologies (Nasdaq: DVAX) is a San Francisco, CA, clinical stage bio-pharma- ceutical company, which discovers and develops a diversified, well-funded pipeline of novel Toll-like Receptor (TLR) product candidates. Based on Dynavax's proprietary technology platform, these products specifically modify the innate immune response to infectious, respiratory, autoimmune, and inflammatory diseases. Dynavax's product programs are supported by global partnerships with leading pharmaceutical companies such as GlaxoSmithKline, and AstraZeneca AB, as well as funding from Symphony Dynamo, Inc. and the National Institutes of Health.
Memory Pharmaceuticals (Nasdaq: MEMY, acquired byROCHE) was a Montvale, NJ, biopharmaceutical company focused on developing innovative drugs for the treatment of debilitating CNS disorders, many of which exhibit significant impairment of memory and other cognitive functions, including Alzheimer's disease and schizophrenia.
Renovis (Nasdaq: RNVS, now merged with Evotec AG, Frankfurt Stock Exchange:EVT) was a San Francisco, CA, biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapeutics for neurological disease.Renovis industrializes neurobiology using proprietary technologies for overcoming nervous system complexity; unique expertise in neuronal identification, isolation, and neurogenomics; relevant preclinical animal models; cutting-edge electrophysiology; and specialized chemistry to discover and develop new drugs for neurological diseases and disorders.
Renovo (LSE: RNVO) is a Manchester, UK based biopharmaceutical company focused on discovery, development and commercialization of drugs that prevent scarring and promote wound healing. The company is currently conducting extensive clinical trials with products to prevent scar formation and accelerate healing. Its innovative products and technologies are based on a portfolio of over 300 patents and patent applications worldwide.
Idun Pharmaceuticals (acquired by Pfizer Inc) was a San Diego, CA, biopharmaceutical company creating innovative human therapeutics with a primary focus on controlling apoptosis, or programmed cell death. It is developing drugs to treat liver disease, inflammation, cancer, and cardiovascular disease.
Agilix Corporation (Proteomics assets acquired byPerkin Elmer) was a New Haven, CT, leading developer of next generation functional genomics and proteomics platform technologies for the systematic discovery and analysis of genes, their protein products and related biological functions. Its technologies and services help reduce the risk, cost and time to market for new pharmaceutical, biotechnology and agricultural products.
NeuroVision was a Singapore headquartered company applying novel technology to improving eyesight without surgery or drugs. Its Neural Vision Correction technology is a non-invasive, patient specific, computerised treatment based on scientifically proven visual stimulation of the neural connections responsible for vision. Its technology and licences have been acquired in a private transaction by a US company.
ASLAN Pharmaceuticals is an Asia enabled pharmaceutical company that develops novel medicines for global markets. Headquartered in Singapore, ASLAN licenses preclinical and early clinical compounds from global pharmaceutical companies, focusing on oncology, respiratory and inflammation diseases, and uses the high quality and efficient development resources available across Asia to progress the drugs through clinical development.
Clearbridge BioMedics is a National University of Singapore spin-off company which aims to be a leader in oncology diagnostics platforms. Its technology enables the label-free isolation, enumeration and retrieval of viable Circulating Tumour Cells (CTCs) from blood and is paving the next generation non-invasive 'liquid biopsy' for cancer.
Kiadis Pharma is a cross-Atlantic oncology focused biopharmaceutical development company with products in different phases of clinical development. The company develops products that offer novel treatment options for terminally ill cancer patients addressing high unmet medical needs. The key focus of Kiadis Pharma is to overcome current limitations and complications of bone marrow transplantation procedures for the treatment of blood cancer patients.
MerLion Pharmaceuticals is a Singapore company focusing on the discovery and development of new drug candidates from natural sources.Its assets and capabilities include an outstanding natural product sample collection, advanced high throughput screening technology, assay development and medicinal chemistry.
NOD Pharmaceuticals is a Shanghai based biotechnology company focusing on innovative deliveries of macromolecular drugs. It is appying its core Nano-particle Oral Delivery technology to develop oral insulin and oral interferon therapies in China to take advantage of the lower cost and short development cycle.
Paratek Pharmaceuticals is a Boston, MA, biopharmaceuticals company engaged in the discovery and commercialization of new therapeutics for the infectious disease market to combat the problem of antibiotic resistance.
Singapore AdvancedBiologics (SABio) was founded by two entrepreneurial researchers at the Duke-NUS Graduate Medical School to provide "Made in Singapore" specialised biologics to the growing biomedical science industry in Singapore and the region. SABio will initially focus on the design, synthesis and validation of specialised biologics, with an initial focus on siRNA, DNA and antibodies.